−0.28USD
−51.93 MUSD
194.62 MUSD
186.68 M
About Akebia Therapeutics, Inc.
Sector
CEO
John P. Butler
Headquarters
Cambridge
Website
Employees (FY)
167
Founded
2007
ISIN
US00972D1054
FIGI
BBG000R33R00
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AKBA is 1.40 USD — it has increased by 0.72% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Akebia Therapeutics, Inc. stocks are traded under the ticker AKBA.
Akebia Therapeutics, Inc. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Akebia Therapeutics, Inc. has a max estimate of 6.00 USD and a min estimate of 4.00 USD.
AKBA earnings for the last quarter are −0.08 USD whereas the estimation was −0.09 USD which accounts for 5.88% surprise. Estimated earnings for the next quarter are −0.04 USD. See more details about Akebia Therapeutics, Inc. earnings.
Akebia Therapeutics, Inc. revenue for the last quarter amounts to 42.00 M USD despite the estimated figure of 48.18 M USD. In the next quarter revenue is expected to reach 55.39 M USD.
Yes, you can track Akebia Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, AKBA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akebia Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 167.00 employees. See our rating of the largest employees — is Akebia Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Akebia Therapeutics, Inc. EBITDA is −8.74 M USD, and current EBITDA margin is −2.17%. See more stats in Akebia Therapeutics, Inc. financial statements.